Despite tremendous recent advances in the treatment of most malignancies, there remain several critical questions for each cancer. This particularly true for the surgical management of solid-organ malignancies. Comparative effectiveness is a relatively new term which encompasses the age-old concepts of how best to treat cancer patients. Comparative effectiveness is defined as the direct comparison of healthcare interventions to determine which work best for which patients when considering the benefits and risks. The Institute of Medicine has defined comparative effectiveness research(CER) as the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. CER is certainly best done with well-conducted randomized controlled trials. Unfortunately, clinical trials are not always feasible owing to the impracticality of conducting the trial, the considerable cost, and the time required to complete the trial. These challenges are even more pronounced with respect to surgical treatment. Thus alternative approaches may need to be considered in order to address pressing questions in the care of the oncology patient. These approaches may include well-conducted retrospective cohort studies from cancer registries and other data sources, decision and cost-effectiveness analyses, and other novel methodologies. This book lays out the current critical questions for each major malignancy and proposes approaches to gain answers to these pressing questions.

The various cell types have traditionally been recognized and classified according to their appearance in the light microscope following the process of fixing, processing, sectioning, and staining tissues that is known as histology. Classical histology has been augmented by
immunohistochemistry (the use of specific antibodies to stain particular molecular species "in situ"). Immunohistochemistry has allowed the identification of many more cell types than could be visualized by classical histology, particularly in the immune system and among the scattered hormone-secreting cells of the endocrine system.
This book discusses all aspects of immunohistochemistry and "in situ" hybridization technologies and the important role they play in reaching a cancer diagnosis. It provides step-by-step instructions on the methods of additional molecular technologies such as DNA microarrays, and microdissection, along with the benefits and limitations of each method. The topics of region-specific gene expression, its role in cancer development and the techniques that assist in the understanding of the molecular basis of disease are relevant and necessary in science today, ensuring a wide audience for this book.
* The only book available that translates molecular genetics into cancer diagnosis
* Provides the readers with tools necessary to perform and optimize sensitive, powerful techniques, including immunohistochemistry and fluorescence in situ hybridization, used in tumor diagnosis
* Written by experts in this field, the book provides theoretical considerations as well as practical approaches to carry out effectively these techniques
* Offers suggestions, tips, cautions, and guidelines to avoid artifacts and misdiagnosis
* Introduces new techniques to detect genes and proteins involved in the initiation and progression of cancer
* Covers the latest developments and a wide range of applications to the detection of antigens and single-copy DNA and RNA
* Written in a uniform format, each chapter includes Introduction, Materials required, step-by-step detailed Methods, Results, Discussion, and comprehensive up-to-date References

In this book, clinicians and basic scientists from USA, India, and other countries discuss the rationales and clinical experiences with targeted approaches to treat, prevent, or manage cancer. Cancer is a hyperproliferative disorder that is regulated by multiple genes and multiple cell signaling pathways. Genomics, proteomics, and metabolomics have revealed that dysregulation of dozens of genes and their products occur in any given cell type that ultimately leads to cancer. These discoveries are providing unprecedented opportunities to tackle cancer by multi-faceted approaches that target these underpinnings. This book emphasizes a multi-targeted approach to treating cancer, the focus of the 5th International Conference on Translational Cancer Research that was held in Vigyan Bhawan, Delhi (India) from Feb 6-9, 2014.

Accumulating evidence supports the role of defects in post-transcriptional gene regulation in the development of cancer. RNA and Cancer examines the recent advances in our understanding of post-transcriptional gene regulation, especially RNA processing and its role in cancer development and treatment. A particular focus is mRNA splicing, but other topics such as microRNAs, mRNA stability, the perinucleolar compartment, and oligonucleotide therapeutics are also covered in detail. All chapters have been written by internationally renowned experts. The book is intended for all with an interest in gene regulation and cancer biology, and especially for those not directly working on RNA biology, including clinicians and medical students. It is hoped that it will stimulate further innovative research collaborations between RNA biologists and cancer researchers to the benefit of patients.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics, including Mdm2 - a regulator of cell growth and death; the systematic progression of human cancer; seizing of T-cells by human T-cell leukemia/lymphoma virus type II; host cell dependent expression of latent Epstein-Barr virus genomes; and gene expression profiling of renal cell carcinoma and its implications in diagnosis prognosis and therapeutics.
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics, including Mdm2 - a regulator of cell growth and death; the systematic progression of human cancer; seizing of T-cells by human T-cell leukemia/lymphoma virus type II; host cell dependent expression of latent Epstein-Barr virus genomes; and gene expression profiling of renal cell carcinoma and its implications in diagnosis prognosis and therapeutics.

The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

* Discusses cancer cell biology in relation to Genome stability and Cell cycle regulation Unique assembly of experts in these fields who wrote a comprehensive and deep up-to-date overview Discusses models for the understanding of DNA damage-dependent signal transduction and regulation in human cells Since the establishment of the DNA structure researchers have been highly interested in the molecular basis of the inheritance of genes and of genetic disorders. Scientific investigations of the last two decades have shown that, in addition to oncogenic viruses and signalling pathways alterations, genomic instability is important in the development of cancer. This view is supported by the findings that aneuploidy, which results from chromosome instability, is one of the hallmarks of cancer cells. Chromosomal instability also underpins our fundamental principles of understanding tumourigenesis: It thought that cancer arises from the sequential acquisition of genetic alterations in specific genes. In this hypothesis, these rare genetic events represent rate-limiting bottlenecks' in the clonal evolution of a cancer, and pre-cancerous cells can evolve into neoplastic cells through the acquisition of somatic mutations. This book is written by international leading scientists in the field of genome stability. Chapters are devoted to genome stability and anti-cancer drug targets, histone modifications, chromatin factors, DNA repair, apoptosis and many other key areas of research. The chapters give insights into the newest development of the genome stability and human diseases and bring the current understanding of the mechanisms leading to chromosome instability and their potential for clinical impact to the reader.

Information gathered from cell-free systems, cell cultures, animal models, and human studies, together provide important insights to our understanding of hormonal cancer causation, development, and prevention; the primary objective of these Symposia. A special emphasis is placed on the two major endocrine-related cancers, that is, breast and prostate. The emerging fields of colon, lung, and pancreatic cancers in relation to hormones are examined.

Edward B. Lewis' science is the bridge linking experimental genetics as conducted in the first half of the 20th century, and the powerful molecular genetic approaches that revolutionized the field in its last quarter. His Nobel Prize winning studies founded the field of developmental genetics and laid the groundwork for our current understanding of the universal, evolutionarily conserved strategies controlling animal development. A lesser-known aspect of Lewis' canon is the pioneering studies he carried out on ionizing radiation and human cancer. In doing so, he was propelled into a public storm over nuclear weapons testing policy. For the first time Lewis' key publications in the fields of genetics, developmental biology, radiation and cancer are compiled within one volume. commentaries on the papers placing them in their scientific and historical context and, throughout, giving insight into Lewis' approach to science and the motivations that drove Lewis' choice of subject matter. This book will be invaluable to a wide audience of professionals in the life and biomedical sciences; including geneticists, developmental biologists, molecular biologists, radiation biologists and cancer researchers. It provides source material for advanced undergraduate and graduate level courses in genetics, developmental biology, radiation and cancer. In addition, historians of science will find it to be a valuable resource both because it contains original research publications and because of the illuminating commentary.

A behind-the-scenes look inside three key trials involving Monsanto's weed killer Roundup, cancer, and the search for justice—written by an expert witness medical oncologist who lived it all. For years, Monsanto declared that their product Roundup, the world's most widely used weed killer, was safe. But that all changed in 2015, when the International Agency for Research on Cancer (IARC) analyzed data from scientific studies and concluded that glyphosate, the active ingredient in Roundup, is probably carcinogenic. The Environmental Protection Agency (EPA) disagreed, other regulatory agencies got involved, and scientists clamored to understand the link between glyphosate and cancer. Toxic Exposure tells the true story of numerous patients who developed non-Hodgkin lymphoma, a form of cancer, after using Roundup and their ensuing trials against Monsanto (now owned by Bayer, one of the largest agrochemical companies in the world). Written by Chadi Nabhan, MD, MBA, a cancer specialist, this is the only book written by an expert physician witness who testified in the first three trials against Monsanto. Dr. Nabhan takes the reader behind the scenes of these pivotal trials, explaining key features of the cases, including how Monsanto downplayed the IARC's scientific conclusions, may have worked to change how the EPA classified glyphosate, and conducted extensive PR campaigns designed to minimize the public's perception of the negative health effects of its product. He also provides details about the other expert witnesses who reviewed the evidence, analyzed the science, and stood up to this agricultural behemoth in the courtroom. Dr. Nabhan tells the inside story of corporate influence, courtroom drama, legal discourse, monumental verdicts, and the ensuing media frenzy surrounding this massive uncovering of the truth and the years of scientific and legal work that led up to it.

Cancer continues to be a growing problem as it is the foremost cause of death worldwide, killing millions of people each year. The number of people battling cancer continues to increase, owing to different reasons, such as lifestyle choices. Clinically, determining the cause of cancer is very challenging and often inaccurate. Incorporating efficient and accurate algorithms to detect cancer cases is becoming increasingly beneficial for scientists in computer science and healthcare, as well as a long-term benefit for doctors, patients, clinic practitioners, and more. Specifically, an automation of computation in machine learning could be a solution in the next generation of big data science technology. Machine Learning in Cancer Research With Applications in Colon Cancer and Big Data Analysis presents algorithms that have been developed to evaluate big data approaches and cancer research. The chapters include artificial intelligence and machine learning approaches, as well as case studies to solve the predictive issues in colon cancer research. This book includes concepts and techniques used to run tasks in an automated manner with the intent to improve better accuracy in comparison with previous studies and methods. This book also covers the processes of research design, development, and outcome analytics in this field. Doctors, IT consultants, IT specialists, medical software professionals, data scientists, researchers, computer scientists, healthcare practitioners, academicians, and students can benefit from this critical resource.

Primary Liver Cancer: Surveillance, Diagnosis and Treatment focuses on the many therapies rapidly evolving to assist with controlling hepatocellular carcinoma as well as emerging technologies to assist in early diagnosis as well as prevention. All chapters are written by experts in their fields and include the most up to date information for diagnosis, treatment, surveillance, epidemiology, staging, recurrence and prevention. This volume will serve as a useful resource for clinical gastroenterologists, hepatologists, oncologists, pathologists, and physicians who treat patients with chronic liver disease and hepatocellular carcinoma.

The book covers the complete field of testis cancer including the germ cell tumors and the stromal tumors, from epidemiology to new chemotherapeutic agents and schedules, throughout genetic features, risk factors, risk adapted treatments, role of different types of surgery and special clinical situations. Special attention is focused on fertility issues, late effects of the primary therapy and the economical aspects of the different treatment policies.

As a result of the third Consensus Conference, a consensual follow-up can be devised and a chapter dedicated to this controversial and not yet defined matter.

This book is the state-of-the-art reference text on testis cancer and is an essential resource for all urologists, medical oncologists and radio-oncologists.

With a particular emphasis on tumor dormancy in breast, lung, prostate, and liver cancers, as well as in melanoma, this first volume of a new Springer series focuses on the interrelationship between biological processes of aging and tumors -- both dormant and quiescent. With detail supplied by numerous international researchers at the forefront of cancer research, the book examines a host of differing aspects of the topic. Featured contributions analyze the role of the quiescent state in regulating hematopoietic and muscle stem cells. They also explore the mediation, by the kinase, in the reversible quiescent state of a subset of ovarian, pancreatic, and colon cancers. The book includes key research on the molecular mechanisms underlying stress-induced cellular senescence, in addition to those governing the accumulation of reactive oxygen species, and the induction of premature senescence. It also provides information on suppressing cellular senescence in the most common, and most aggressive malignant primary brain tumor in humans, glioblastoma multiforme. With comprehensive and cutting-edge information on therapeutic interventions and on the correct diagnosis of relevant neoplasms, and with numerous color illustrations, this is the most up-to-date assessment of current medical knowledge in this crucial area of medical research.

This book presents a comprehensive overview of current state-of-the-art clinical physiological imaging of brain tumors. It focuses on the clinical applications of various modalities as they relate to brain tumor imaging, including techniques such as blood oxygen level dependent functional magnetic resonance imaging, diffusion tensor imaging, magnetic source imaging/magnetoencephalography, magnetic resonance perfusion imaging, magnetic resonance spectroscopic imaging, amide proton transfer imaging, high angular resolution diffusion imaging, and molecular imaging. Featuring contributions from renowned experts in functional imaging, this book examines the diagnosis and characterization of brain tumors, details the application of functional imaging to treatment planning and monitoring of therapeutic intervention, and explores future directions in physiologic brain tumor imaging. Intended for neuro-oncologists, neurosurgeons, neuroradiologists, residents, and medical students, Functional Imaging of Brain Tumors is a unique resource that serves to advance patient care and research in this rapidly developing field.

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases, histone deacetylases, oxidative stress and proteotoxic stress pathways and pharmacogenomic signature profiling) in resistant cancer cells. The mechanisms of action and resistance of proteasome inhibitors, such as bortezomib and carfilzomib in human cancers, including multiple myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are explored in depth in this volume.

This timely volume unveils the most current discoveries of the mechanisms behind proteasome inhibitor resistance, which will help illuminate the future of cancer therapies.

A state-of-the art collection of readily reproducible laboratory methods for assessing chemosensitivity in vitro and in vivo, and for assessing the parameters that modulate chemosensitivity in individual tumors. Chemosensitivity, Volume 2: In Vivo Models, Imaging, and Molecular Regulators contains cutting-edge protocols for classifying tumors into response categories and for customizing therapy to individuals. These readily reproducible techniques allow measurements of DNA damage, apoptotic cell death, and the molecular and cellular regulators of cytotoxicity, as well as in vivo animal modeling of chemosensitivity. A companion volume, Volume 1: In Vitro Assays contains in vitro and in vivo techniques to identify which new agents or combination of agents are effective for each type of tumor

Lung cancer is the leading cause of cancer-related mortality. Metastatic lung cancer is responsible for more than ninety percent of lung cancer related deaths. However, relatively little progress has been made in understanding the process of lung cancer metastasis. The two main aims of this book are a) to introduce clinical aspects to basic scientists and basic molecular and cellular concepts to clinical investigators, in order to promote collaboration and foster much needed translational research; and b) to introduce new and emerging concepts and approaches in metastasis research to lung cancer research community at large. In this attempt, the book will cover a broad spectrum of subjects ranging from the current trends in the clinical management of the metastatic disease, to the systems biology approach for gaining insights into the mechanisms of metastasis. Some of the subjects covered will include: defining basic hallmarks of a metastatic cell, the concept of tumor stem cells, epithelial-mesenchymal transitions, evasion of immune-surveillance, tumor-stromal interactions, angiogenesis, molecular imaging and biomarker discovery.

Intraperitoneal Cancer Therapy investigates intraperitoneal chemotherapy in a variety of complex and interesting ways. The volume details major clinical trails to date, including immunotherapy, hyperthermic treatment of colo-rectal and ovarian cancers. Authors also examine regional approaches to therapy, systemic therapy, and the use of carboplatin and paclitaxel as the standard treatment for women with stages III and IV ovarian cancer. Other chapters also investigate techniques and procedures in treatment, as well as the future direction of both normothermic and hyperthermic intraperitoneal chemotherapy.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics.
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics.

The detailed and comprehensive observations presented in this book on acquired cystic disease of the kidney and renal cell carcinoma in dialysis patients are drawn from the author 's decades of experience. Beginning with the first clinical case in 1978 and including subsequent follow-up studies and questionnaires, the volume is an excellent clinical reference for practicing physicians. Color illustrations and numerous case studies assist the reader.

A panel of internationally recognized research scientists and clinical investigators brings together a diverse collection of readily reproducible methods for identifying and quantifying a large number of specific genetic abnormalities associated with the broad spectrum of myeloid malignancies. Highlights include techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of AML by DNA-oligonucleotide microarrays, and detection of the V617F JAK2 mutation in myeloproliferative disorders. In addition to gene rearrangments, other prognostically relevant molecular lesions such as FLT3 mutations and WT-1 overexpression are covered.

Breast cancer survivor Patty Gelman recounts her journey through "Cancer World" in a series of anecdotes, chronicling her year-long struggle with the disease in an upbeat, colloquial, and often candidly funny way. Typical of her unyieldingly positive attitude is the way that Gelman breaks the news to her mother, also a cancer survivor: "'Well, it's my turn now!'" Instead of keeping a journal during her treatment, Gelman preferred to share her experiences online, a choice she found surprisingly therapeutic. What started as periodic e-mails to family and friends soon developed into a book many cancer patients are turning to for hope. E-mails also served as an outlet and a built-in support group when her mother contracted lung cancer and passed on within the year. Gelman's story becomes larger than her disease, exploring the task of coping with the unexpected, and the value of family.

This volume will be the first to provide a comprehensive description of tumor dormancy. It will define the clinical and biological aspects of this phenomenon, as well as the cellular and molecular mechanisms associated with tumor dormancy. Chapters will be authored by world-renewed experts who are conducting cutting-edge research in the field. A unique feature will be a conclusive paragraph detailing future development and foreseeable clinical applications at the end of each chapter. The volume will serve as a fundamental instrument for every researcher and clinician interested in the field of tumor dormancy as well as a means of disseminating stimulating concepts and prompting the development of innovative technological solutions.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics, including HAMLET and tumor cells; survivin and apoptosis control; retroviral insertional mutagenesis; aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis; and epigenetic variability and the evolution of human cancer.
The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents outstanding and original reviews on a variety of topics, including HAMLET and tumor cells; survivin and apoptosis control; retroviral insertional mutagenesis; aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis; and epigenetic variability and the evolution of human cancer.